Table 2 Associations between ERCC1 expression and clinical characteristics in groups with or without adjuvant chemotherapy
From: ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
Characteristic | Adjuvant chemotherapy (n = 57) | No adjuvant chemotherapy (n = 36) | Total (n = 93) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|  | ERCC1 (+) (n = 34) | ERCC1 (−) (n = 23) | P | ERCC1 (+) (n = 20) | ERCC1 (−) (n = 16) | P | ERCC1 (+) (n = 54) | ERCC1 (−) (n = 39) | P |
Sex | Â | Â | 0.49 | Â | Â | 0.19 | Â | Â | 0.21 |
Men | 29 (85.3%) | 18 (78.3%) | Â | 19 (95.0%) | 13 (81.3%) | Â | 48 (88.9%) | 31 (79.5%) | Â |
Women | 5 (14.7%) | 5 (21.7%) | Â | 1 (5.0%) | 3 (18.8%) | Â | 6 (11.1%) | 8 (20.5%) | Â |
Age at operation | Â | Â | 0.35 | Â | Â | 0.24 | Â | Â | 0.92 |
≥ 65 years | 8 (23.5%) | 8 (34.8%) |  | 15 (75.0%) | 9 (56.3%) |  | 23 (42.6%) | 17 (43.6%) |  |
< 65 years | 26 (76.5%) | 15 (65.2%) | Â | 5 (25.0%) | 7 (43.8%) | Â | 31 (57.4%) | 22 (56.4%) | Â |
T stage | Â | Â | 0.68 | Â | Â | 0.65 | Â | Â | 0.99 |
T1-T2 | 2 (5.9%) | 2 (8.7%) | Â | 9 (45.0%) | 6 (37.5%) | Â | 11 (20.4%) | 8 (20.5%) | Â |
T3-T4 | 32 (94.1%) | 21 (91.3%) | Â | 11 (55.0%) | 10 (62.5%) | Â | 43 (79.6%) | 31 (79.5%) | Â |
N stage | Â | Â | 0.48 | Â | Â | 0.58 | Â | Â | 0.13 |
Node negative | 16 (47.1%) | 13 (56.5%) | Â | 16 (80.0%) | 16 (100%) | Â | 32 (59.3%) | 29 (74.4%) | Â |
Node positive | 18 (52.9%) | 10 (43.5%) | Â | 4 (20.0%) | 0 (0%) | Â | 22 (40.7%) | 10 (25.6%) | Â |
Histologic type | Â | Â | 0.64 | Â | Â | 0.87 | Â | 0.69 | Â |
Squamous differentiation | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| Â | 6 (17.6%) | 3 (13.0%) | Â | 1 (5.0%) | 1 (6.3%) | Â | 7 (13.0%) | 4 (10.3%) | Â |
Other types | 28 (82.4%) | 20 (87.0%) | Â | 19 (95.0%) | 15 (93.8%) | Â | 47 (87.0%) | 35 (89.7%) | Â |
Pathologic grade* | Â | Â | 0.74 | Â | Â | 0.69 | Â | Â | 0.22 |
Grade 2 | 2 (5.9%) | 5 (21.7%) | Â | 2 (10.0%) | 1 (6.3%) | Â | 6 4 (7.4%) | (15.4%) | Â |
Grade 3 | 32 (94.1%) | 18 (78.3%) | Â | 18 (90.0%) | 15 (93.8%) | Â | 50 (92.6%) | 33 (84.6%) | Â |